Marc Hoffmann, MD
Hematology & Oncology · Overland Park, KSNPI 1386806941
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $103,306 of the $153,346 with a category attached, or 67.4%. 26 manufacturers reported payments, led by Johnson & Johnson at 27.1% of the total. Among hematology & oncology clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 200 payments — averaging $766.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$41K
- Pharmacyclics LLC, An Abbvie Company$21K
- Beone Medicines USA, Inc.$20K
- Genmab U.S., Inc.$19K
- AstraZeneca$12K
- AbbVie$10K
- plus $30K from 20 others
Across 1,014 payments — averaging $13,310 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$4.1M
- Beone Medicines Ltd.$2M
- Bristol Myers Squibb$1.7M
- Eli Lilly$1.1M
- TG Therapeutics, Inc.$1M
- Genentech, Inc.$864K
- plus $2.8M from 11 others
What the payments were for
- Consulting fees$103,30667%
- Speaking & faculty fees$36,02523%
- Travel & lodging$6,9235%
- Food & beverage$6,9805%
- Education$1120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 26 | $41,486 |
| Pharmacyclics LLC, An Abbvie Company | 40 | $20,882 |
| Beone Medicines USA, Inc. | 18 | $20,473 |
| Genmab U.S., Inc. | 13 | $18,788 |
| AstraZeneca | 12 | $11,790 |
| AbbVie | 22 | $9,754 |
| Beigene USA, Inc. | 10 | $6,311 |
| Novartis | 6 | $5,703 |
| Gilead | 3 | $3,992 |
| ADC Therapeutics America, Inc. | 14 | $3,479 |
| Genentech USA, Inc. | 5 | $3,296 |
| Novartis Pharma AG | 3 | $2,178 |
| Janssen Global Services, LLC | 3 | $1,640 |
| BTG International Inc. | 2 | $1,068 |
| Eli Lilly | 2 | $677 |
| Epizyme, Inc. | 1 | $525 |
| Adaptive Biotechnologies Corporation | 3 | $338 |
| Genentech, Inc. | 3 | $261 |
| Bristol Myers Squibb | 5 | $239 |
| Lilly USA, LLC | 2 | $165 |
| TG Therapeutics, Inc. | 1 | $120 |
| Secura Bio, Inc. | 1 | $102 |
| Merck | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $14 |
| Janssen Scientific Affairs, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$153,346 in reported general payments places this provider in the 95th percentile of 97 hematology & oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 115 | $1,578,295 |
| JaypircaPirtobrutinib | 48 | $959,388 |
| VenclextaVenetoclax | 47 | $509,942 |
| ImbruvicaIbrutinib | 23 | $273,024 |
| PromactaEltrombopag Olamine | 13 | $272,848 |
| XareltoRivaroxaban | 32 | $35,769 |
| Deferasirox | 14 | $9,370 |
| Enoxaparin Sodium | 18 | $8,777 |
| Acyclovir | 201 | $5,931 |
| Entecavir | 26 | $4,772 |
| Duloxetine Hcl | 25 | $1,376 |
| ValacyclovirValacyclovir Hcl | 24 | $1,298 |
| Pantoprazole Sodium | 86 | $1,073 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 61 | $620 |
| Omeprazole | 24 | $595 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $6,311 | $1,578,295115 claims |
| Lilly USA, LLCJaypirca | $165 | $959,38848 claims |
| AbbVieVenclexta | $9,754 | $509,94247 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $20,882 | $273,02423 claims |
| NovartisPromacta | $5,703 | $272,84813 claims |
| Johnson & JohnsonXarelto | $41,486 | $35,76932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 97 hematology & oncology providers in Kansas.
Other hematology & oncology in Overland Park
- Dhruv BansalOverland Park$79K
- Sukumar EthirajanOverland Park$61K
- Joseph StilwillOverland Park$2K
- Gregory CraneOverland Park$2K
- Richard McKittrickOverland Park$1K
- Rachana YendalaOverland Park$1K
- Shaker DakhilWichita$579K
- Quoc TruongWichita$539K
- Bassam MattarWichita$221K
- Priyanka SharmaWestwood$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.